Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Common Equity: 2020-2024

Historic Common Equity for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $3.6 million.

  • Oncology Institute's Common Equity fell 17927.92% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.3 million, marking a year-over-year decrease of 17927.92%. This contributed to the annual value of $3.6 million for FY2024, which is 9370.63% down from last year.
  • According to the latest figures from FY2024, Oncology Institute's Common Equity is $3.6 million, which was down 9370.63% from $57.0 million recorded in FY2023.
  • In the past 5 years, Oncology Institute's Common Equity ranged from a high of $123.2 million in FY2022 and a low of $3.6 million during FY2024
  • In the last 5 years, Oncology Institute's Common Equity had a median value of $57.0 million in 2023 and averaged $63.2 million.
  • As far as peak fluctuations go, Oncology Institute's Common Equity skyrocketed by 27065.94% in 2021, and later crashed by 9370.63% in 2024.
  • Oncology Institute's Common Equity (Annual) stood at $28.1 million in 2020, then soared by 270.66% to $104.2 million in 2021, then rose by 18.26% to $123.2 million in 2022, then plummeted by 53.7% to $57.0 million in 2023, then crashed by 93.71% to $3.6 million in 2024.
  • Its Common Equity stands at $3.6 million for FY2024, versus $57.0 million for FY2023 and $123.2 million for FY2022.